| 1 |
CONG Y, LI J, LOU D, et al. Analysis of compliance issues and influencing factors in the management of BSL-2 laboratories for pathogenic microorganisms in Lishui, China[J]. Frontiers in bioengineering and biotechnology, 2025, 13: 1637056.
|
| 2 |
XU Y, YU H, CHEN J, et al. Exploration of a training model for laboratory personnel based on ISO 15189[J]. Clinical laboratory, 2025, 71(6):10.7754/Clin.Lab.2024.241134.
|
| 3 |
杨松, 董静肖, 赵秀英. 检验与临床沟通状况及临床需求分层的调研与分析[J]. 临床检验杂志, 2023, 41(12): 945-946.
|
| 4 |
付宏煜, 朱志宸, 冯立, 等. 711名儿童患者输血反应回顾性分析[J]. 中国输血杂志, 2024, 37(6): 678-683.
|
| 5 |
INTERNATIONAL ORGANIZATION FOR STANDARDIZATION. Medical laboratories-Application of risk management to medical laboratories: ISO 22367:2026[S]. Geneva: International Organization for Standardization, 2026.
|
| 6 |
何菁, 胡长爱, 杨大干. ISO 15189:2012和ISO 15189:2022的不符合对照分析及换版策略[J]. 临床检验杂志, 2024, 42(4): 304-307.
|
| 7 |
DAVID R E. Approaching risk management in medical laboratories[J]. Romanian journal of laboratory medicine, 2022, 30(2): 125-139.
|
| 8 |
ALOTAIBI A M E, HAMDI M H, ALOMI A M, et al. Assessment of risk management practices in clinical laboratories and their impact on patient safety[J]. Journal of angiotherapy, 2024, 8(1): 1-10.
|
| 9 |
LUAN X, KE L, FENG M, et al. Risk management in POCT blood glucose monitoring: FMEA approach aligned with ISO 15189:2022[J]. PLoS One, 2025, 20(3): e0319817.
|
| 10 |
应琪明, 陈鲁燕, 董科迪, 等. PDCA框架下多院区Rh血型抗原精准输注策略优化[J]. 中国输血杂志, 2025, 38(1): 106-111.
|
| 11 |
ROBINS R D L, HARAN H, PUNNIAKOTI S, et al. Enhancing blood centre operations through Lean Six Sigma methodologies-A prospective interventional study in the blood donor area of a tertiary care blood centre[J]. Transfusion clinique et biologique: Journal de la Société Française de Transfusion Sanguine, 2026, 33(1): 3-9.
|
| 12 |
GUPTA M. Making transfusion medicine a journey from good to great by using quality indicators and bringing in continuous quality improvement[J]. Global journal of transfusion medicine, 2021, 6(2): 127-134.
|
| 13 |
CHEN P, CHEN X, XIA Y, et al. From assessment to action: Experience from a quality improvement initiative integrating indicator evaluation and adverse event analysis in a clinical laboratory[J]. Clinical chemistry and laboratory medicine, 2025, 63(12): 2415-2424.
|
| 14 |
KATHRYN BOHN M, AUGUSTIN R, CHARTIER L, et al. Primer Part 1 - Preparing a laboratory quality improvement project[J]. Clinical biochemistry, 2024, 127-128: 110764.
|
| 15 |
TAGARAM S D, CHEN C. Quality tools and techniques (fishbone diagram, pareto chart, process map)[M]. Treasure Island (FL): StatPearls publishing, 2026.
|
| 16 |
YUN Y M. Apolipoprotein B, non-HDL cholesterol, and LDL cholesterol as markers for atherosclerotic cardiovascular disease risk assessment[J]. Annals of laboratory medicine, 2023, 43(3): 221-222.
|
| 17 |
SOFFER D E, MARSTON N A, MAKI K C, et al. Role of apolipoprotein B in the clinical management of cardiovascular risk in adults: An expert clinical consensus from the National Lipid Association[J]. Journal of clinical lipidology, 2024, 18(5): e647-e663.
|
| 18 |
HANSEN M K, MORTENSEN M B, OLESEN K K W, et al. Non-HDL cholesterol and residual risk of cardiovascular events in patients with ischemic heart disease and well-controlled LDL cholesterol: A cohort study[J]. The Lancet regional health. Europe, 2024, 36: 100774.
|
| 19 |
LEE J H, AHN S G, JEON H S, et al. Remnant cholesterol as a residual risk in atherosclerotic cardiovascular disease patients under statin-based lipid-lowering therapy: A post hoc analysis of the RACING trial[J]. Journal of clinical lipidology, 2024, 18(6): e905-e914.
|
| 20 |
JO S H. Triglycerides, triglyceride-rich lipoproteins, and remnant cholesterol in atherosclerotic cardiovascular disease[J]. Journal of lipid and atherosclerosis, 2025, 14(3): 247-257.
|
| 21 |
AVERNA M, CEFALÙ A B. LP(a): The new marker of high cardiovascular risk[J]. Nutrition, metabolism, and cardiovascular diseases, 2025, 35(3): 103845.
|
| 22 |
YANG L, YUE Q, FANG F, et al. Effect of dual residual risk of cholesterol and inflammation on all-cause mortality in patients with cardiovascular disease[J]. Cardiovascular diabetology, 2023, 22(1): 96.
|
| 23 |
RIDKER P M, MACFADYEN J G, THUREN T, et al. Residual inflammatory risk associated with interleukin-18 and interleukin-6 after successful interleukin-1β inhibition with canakinumab: Further rationale for the development of targeted anti-cytokine therapies for the treatment of atherothrombosis[J]. European heart journal, 2020, 41(23): 2153-2163.
|
| 24 |
BALLOUT R A, REMALEY A T. GlycA: A new biomarker for systemic inflammation and cardiovascular disease (CVD) risk assessment[J]. Journal of laboratory and precision medicine, 2020, 5: 17.
|
| 25 |
WANG H, NIE H, BU G, et al. Systemic immune-inflammation index (SII) and the risk of all-cause, cardiovascular, and cardio-cerebrovascular mortality in the general population[J]. European journal of medical research, 2023, 28(1): 575.
|
| 26 |
LI Q, YU Y, ZHOU Y Q, et al. Predictive value of neutrophil-to-lymphocyte ratio in coronary chronic total occlusion patients[J]. Journal of geriatric cardiology, 2024, 21(5): 542-549.
|
| 27 |
MA D, GAO X, WANG L, et al. Circulating tumor DNA for MRD detection in colorectal cancer: Recent advances and clinical implications[J]. Biomarker research, 2025, 13(1): 89.
|
| 28 |
傅琤琤. 《基于骨髓样本的多发性骨髓瘤微小残留病灶检测专家共识(2024年版)》解读[J]. 临床血液学杂志, 2024, 37(9): 607-611.
|
| 29 |
PELTIER L, VAN AELST S, PEETERS B, et al. Patient risk management in laboratory medicine: An international survey to assess the severity of harm associated with erroneous reported results[J]. Clinical chemistry and laboratory medicine, 2025, 63(8): 1548-1554.
|
| 30 |
GIESRIEGL F, MRAZEK C, CADAMURO J. How laboratory medicine will change in the near future: integrating artificial intelligence, automation, and human expertise in the era of industry 5.0[J]. Journal of laboratory and precision medicine, 2025, 10: 12.
|
| 31 |
华东地区采供血机构协作组共识项目专家组, 庄云龙, 吴玉清, 等. 采供血机构血液和环境卫生质量检查中国专家共识[J]. 临床输血与检验, 2026, 28(1): 9-17.
|
| 32 |
王贝, 刘佳惠. 基于ISO 15189质量体系的血站核酸实验室的风险管理[J]. 江苏卫生事业管理, 2024, 35(5): 737-742.
|
| 33 |
张巧琳, 韩凤娇, 刘静怡, 等. 重庆市单采血小板献血者经血传播HIV的残余风险评估[J]. 检验医学与临床, 2024, 21(10): 1484-1487.
|
| 34 |
HUSEYNOVA E, HAYNES J, NOTARI E P, et al. Incidence and window period residual risk of human immunodeficiency virus, hepatitis B virus, and hepatitis C virus in United States blood donations, 2017 to 2023: The transfusion-transmissible infections monitoring system[J]. Transfusion, 2025, 65(10): 1876-1887.
|
| 35 |
葛文超, 吕永磊, 陈明军, 等. 郑州地区无偿献血者血液筛查中丙型肝炎病毒残余风险的评估[J]. 中国输血杂志, 2022, 35(5): 546-549.
|
| 36 |
KLEINMAN S, BUSCH M P, KORELITZ J J, et al. The incidence/window period model and its use to assess the risk of transfusion-transmitted human immunodeficiency virus and hepatitis C virus infection[J]. Transfusion medicine reviews, 1997, 11(3): 155-172.
|
| 37 |
余呈丽, 李瑞娟. 无偿献血人群血液筛查后乙型肝炎病毒传播的残余风险评估[J]. 医学信息, 2024, 37(13): 49-51, 55.
|
| 38 |
沈欣堂, 宋和蔚, 曲家黎, 等. 运用流行率-窗口期模型对烟台地区2018—2022年经输血传播的乙型肝炎、丙型肝炎和人类免疫缺陷病毒残余风险的评估[J]. 首都医科大学学报, 2025, 46(5): 898-906.
|
| 39 |
WHITE S K, WALKER B S, POTTER S, et al. Estimating the incidence of transfusion-associated circulatory overload using active surveillance: A systematic review and meta-analysis[J]. Transfusion, 2025, 65(6): 1061-1071.
|
| 40 |
WHITE S K, WALKER B S, SCHMIDT R L, et al. The incidence of transfusion-related acute lung injury using active surveillance: A systematic review and meta-analysis[J]. Transfusion, 2024, 64(2): 289-300.
|
| 41 |
YILDIZ A, EVREN G, ZIHAR B, et al. Non-hemolytic acute transfusion reactions: the impact of patient and blood product characteristics[J]. Postgraduate medicine, 2024, 136(7): 726-730.
|
| 42 |
FU Z, HAO X, GAO W, et al. Research progress in RBC alloimmunization[J]. Frontiers in immunology, 2025, 16: 1677581.
|
| 43 |
COATES T D. Management of iron overload: Lessons from transfusion-dependent hemoglobinopathies[J]. Blood, 2025, 145(4): 359-371.
|
| 44 |
BADAWI M A. Artificial intelligence in blood donor management: A narrative review[J]. Vox sanguinis, 2026, 121(4): 406–416.
|
| 45 |
COELHO H, SILVA F, CORREIA M, et al. Artificial intelligence in patient blood management: A systematic review of predictive, diagnostic, and decision support applications[J]. Journal of clinical medicine, 2025, 14(23): 8479.
|